Yes, the glucose monitoring market is huge. It is important to know what is particularly new, or

different in what is being reviewed in order to gauge any potential impact in the sales/revenue area. Negative decisions by the FDA have a tendency to be taken advantage of by certain market forces, and share prices can be crushed, though it is usually medications that bear the brunt. We are now connected to this company, and though we are experiencing a good deal of deep water, pressure-at-depth sensations of our own making, we certainly don't want more. More information would definitely be helpful.